 
 
 
Clinimark  
[ADDRESS_432980]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   1   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
CLINIMARK Test  Plan  
Respi[INVESTIGATOR_348525] - Gabi SmartCare Gabi Band  
PR 2022 -495 
 
COMMERCIAL SPONSOR:  
Gabi SmartCare  SA 
Rue Emile Francqui 6 , 2nd Floor  
1435 Mont -Saint -Guibert Belgium  
   
Document 
Ownership:  Document is in accordance with Code of Federal Regulations for Non -Significant Risk Investigations and 
ISO [ZIP_CODE] :2011  where applicable  
Function, Title  Name  [CONTACT_164300], Associate 
Researcher  Carolyn Cohen  
 21 Sep 2022  
 
Document 
Approver:  The document approvers are listed below:  
Function, Title  Name  [CONTACT_164300], Chief Clinical 
Officer  Paul Batchelder  
 [ADDRESS_432981]  Carton    
 
Revision 
History:  
Revision  Date  Revision Description  
Version 1  21 Sep 2022  Initial issue  
   
   
 
Author:   Carolyn Cohen  
Associate Researcher  
CLINIMARK, LLC  
Avista Adventist Hospi[INVESTIGATOR_164261]  
[ADDRESS_432982]  
Louisville, CO [ZIP_CODE]  
 
  
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
22-sept.-[ADDRESS_432983]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   2   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Respi[INVESTIGATOR_348525] - Gabi SmartCare Gabi Band   
PR 2022 -495 
 
ETHICS COMMITTEE REVIEW:  
Salus Institutional Review Board  
[ADDRESS_432984] 00 Austin, TX [ZIP_CODE]  
John C. Lewis, DVM: Chairman Board 1  
Charles F. Ryan, PhD, RPh:  Vice -Chair Board 1  
Patricia L. Gonzales, PharmD : Chairman Board 2   
Alexander Kenaston, RN, MS, PhD, CIP: Chairman Board 3  
 
STUDY PROCEDURE:   
Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi Band  
Clinimark Study ID# PR 2022 -495 
 
COMMERCIAL SPONSOR:  
Gabi SmartCare  
Rue Emile Francqui 6 2nd Floor  
1435 Mont -Saint -Guibert Belgium  
 
PRINCIPAL INVESTIGATOR:   
[INVESTIGATOR_136170] , MD  
Avista Adventist Hospi[INVESTIGATOR_307], Staff Anesthesiologist  
[ADDRESS_432985], Golden, Colorado [ZIP_CODE]  
 
MEDICAL OVERSIGHT:  
Arthur Cabrera, MD  
Avista Adventist Hospi[INVESTIGATOR_307], Staff Anesthesiologist  
[ADDRESS_432986]  
Louisville, CO [ZIP_CODE]  
 
STUDY SITE:  
Clinimark,  Site ID# [ADDRESS_432987] ive Suite 20  
Louisville, CO [ZIP_CODE]  
 
 
  
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_432988]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   3   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Clinimark Statements  
Confidentiality  
The information contained in this document is confidential and is intended for the use of clinical investigators.  It 
will not be copi[INVESTIGATOR_348526] , unless 
such persons are bou nd by a confidentiality agreement with Clinimark or Gabi SmartCare . 
 
Impartiality  
Clinimark is committed to maintaining impartiality of laboratory and study activities.   Personnel are trained on 
processes and protocols are followed to ensure conformity of the activities. Commercial, financial and other 
pressures are not allowed to compromise the impartiality of laboratory activities. This includes those risks that 
arise from lab activities, lab relationships, or from the relationships of its personnel.  
 
The risk of Impartiality is mitigated by [CONTACT_348553], 
contractual arrangements, and standards or guidance documents if applicable.  
 
Glossary  
• CIP - Clinical Investigation Plan  
• FDA – Food and Drug Admini stration  
• IRB – Independent Review Board  
• ISO – the International Organization for Standardization  
• NIST – National Institute of Standards and Technology, NIST  is the federal technology agency that works 
with industry to develop and apply technology, measure ments, and standards.  
• Reference – established accuracy used for clinical evaluations of other instruments  
• Device Under Test (DUT) – the device being clinically evaluated    
• NSR – Non Significant Risk  
• PPG - Photoplethysmography  
• bpm – beats per minute, in regards to heart or pulse rate  
• BPM – Breaths per minute, in regards to respi[INVESTIGATOR_697]  
• EtCO 2 – End Tidal Carbon Dioxide  
• RR – Respi[INVESTIGATOR_1516]/Respi[INVESTIGATOR_13581]  
• PR – Pulse Rate  
• ROI  – Region of Interest  
• ARMS - Accuracy Root Mean Square  
 
Where:  
o ARMS is the accuracy root mean square.  
o DUT is the test device during sample i.  
o Ref is the Reference Respi[INVESTIGATOR_13581] (EtCO 2) during sample i.  
o n is the number of points.  ni i
Armsn
if DUTå -
==12) Re (
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_432989]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   4   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Respi[INVESTIGATOR_348525] - Gabi SmartCare Gabi Band   
PR [ADDRESS_432990] a Respi[INVESTIGATOR_348527] , an FDA cleared End Tidal Carbon Dioxide monitor (GE Datex -Ohmeda).  
 
The testing will be conducted in order to obtain a full data set for Verification  on a minimum of 2 3 participant s.  
Multiple developmental phases may be conducted and will be reviewed for  readiness for continuation to 
Verification . If modifications are warranted, the initial data sets will be used for algorithm development.  The study 
will be split up into two phases:  
• Phase I with a minimum of 8 subjects  
• Phase II with a minimum of [ADDRESS_432991] measurement using end tidal carbon dioxide (EtCO 2) respi[INVESTIGATOR_697] . 
 
The medical device studied under this protocol will be the non -invasive  and investigational Gabi SmartCare Gabi 
Band . All appropriate preliminary  testing on the Gabi SmartCare Gabi Band  has been successfully performed and 
demonstrates safety and efficacy for use in hu man studies prior to Clinimark’s receipt of the devices. Gabi 
SmartCare Gabi Band  is a non -invasive device that allows for real-time, remote monitoring  using a sensor applied 
on the participan t’s upper arm.   
 
Protocol Overview  
After IRB  approval, a minimum of [ADDRESS_432992] participant s will be enrolled for the verification  study 
population .  A maximum of 60 participant s will be enrolled . An attempt will be made to include 3 darkly pi[INVESTIGATOR_348528] s or 15% of the participant  pool (whichever is larger).  Participants  will be from 0 -5 years of age with the 
following distribution:  
 
Population  Age Population  Requirement  
Neonates  0-28 days No requirement  
Infant  >1 month – 24 months  Minimum 30% of participants  
Pediatrics  >2 years – 5 years  Minimum 30% of participants  
 
Each participant  is expected to take 1-2 hours, including paperwork, sensor application, and a maximum of 60 
minutes of data collection. Each participant  will be connected to a commonly used End Tidal Carbon Dioxide 
monitor (GE Datex -Ohmeda) and the Gabi SmartCare Gabi Band. The end tidal carbon dioxide (EtCO 2) monitor will 
determine performance of respi[INVESTIGATOR_348529] (GE Healthcare S5 Compact Monitor  with M-COVX (K001814) or 
E-CaiO (K051092) modules ). Each participant  will be instrumented with neonatal or pediatric nasal cannula that 
allows for measurement of the EtCO 2.  SpO 2 sensors may be placed on the feet and/or toes for safety monitoring 
purposes . 
 
Data will be simultaneously and continuously recorded from the Reference EtCO [ADDRESS_432993] (DUT). Periods of quiet will be encouraged.   Data will be marked for stable quiet periods  that are useable for 
analysis . There is no additio nal follow -up required for the investigation.     
 
One minute epoch s will be generated  from the stable data periods for analysis .   For verification , the  Reference  
EtCO 2 waveform will be scored by [CONTACT_348554][INVESTIGATOR_348530]  (See Appendix B: Sample Waveform 
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_432994]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   5   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Scoring Form for an example).  The reviewers counting the raw EtCO [ADDRESS_432995] device.  The DUT data will be averaged over the corresponding  one minute period.  The Accuracy root -
mean-square (A rms) will be the basis for evaluation and acceptance.  
 
To ‘Pa ss’ this test the Gabi SmartCare Gabi Band  (Device Under Test ) must demonstrate a n Accuracy root -mean -
square (A rms) of ≤3.0 breaths per minute  when compared to the Reference EtCO 2 monitor .  
 
Study Population  
The study population will include a minimum of 23 neonates, infants, and pediatrics from 0 -12 years of age . A 
maximum of 60 participant s will be enrolled.   The participant  selection will be an equitable distribution of males 
and females of any race with varying skin tones.  An attempt will be made to include 3 darkly pi[INVESTIGATOR_348528] s  (Fitzpatrick 5 or 6) or 15% of the participant  pool (whichever is larger).  
 
The parents  or guardian of the participant s must understand the study and consent to their child’s participation in 
the study by [CONTACT_246629]. Subjects 7 to 12 years of age will be provided an Assent. The 
study will be explained within his /her ability to understand. Participant  enrollment and participation in this clinical 
study is based on meeting the inclusion criteria and none of the exclusion criteria, a satisfactory screening , and the 
participant  and data demographics needed for the st udy.   
 
Inclusion Criteria  
• Ability of the parent or guardian to understand and provide written informed consent  
• Participant  is 0 to 12 years of age  
• Subjects that are between [ADDRESS_432996] provide Assent to participate in the study  
 
Population Criteria to be Included  
• A minimum of 30% of participants will be >1 month to 24 months old  
• A minimum of 30% of participants will be >2 years to 12 year  
 
Exclusion Criteria  
• Participants evaluated by [CONTACT_348555] t o be medically unsuitable or have 
self-reported health conditions that are currently unstable as identified in the Participant Demographics 
and Screening Record Form  
• Participant  has injuries, deformities or abnormalities that may prevent proper application  of the device 
under test  
• Participant s with severe contact [CONTACT_136184], latex or other materials found in pulse 
oximetry sensors, ECG electrodes, or other medical sensors (self -reported)  
 
It is expected that the data collection will take  two days for Phase I and four days  for Phase II. There is no 
additional follow -up required for the investigation.  
 
  
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_432997]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   6   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi Band   
PR 2022 -495 
 
Table of Contents  
Clinimark Statements  ................................ ................................ ................................ ................................ ....................  3 
Glossary  ................................ ................................ ................................ ................................ ................................ ........  3 
Summary  ................................ ................................ ................................ ................................ ................................ .......  4 
Objectives of the Clinic al Investigation Plan  ................................ ................................ ................................ .............  4 
Background  ................................ ................................ ................................ ................................ ...............................  4 
Protocol Overview  ................................ ................................ ................................ ................................ ....................  4 
Study Popula tion ................................ ................................ ................................ ................................ .......................  5 
Inclusion Criteria  ................................ ................................ ................................ ................................ ...................  5 
Population Criteria to be Included  ................................ ................................ ................................ ........................  5 
Exclusion Criteria  ................................ ................................ ................................ ................................ ..................  5 
Table of Contents  ................................ ................................ ................................ ................................ ..........................  6 
Objectives of the Clinical Investigation Plan  ................................ ................................ ................................ .................  9 
Identification and Description of the Investigational Device  ................................ ................................ ........................  9 
Data Acquisition System for the Investigational Device  ................................ ................................ .........................  10 
Safety Equipment  ................................ ................................ ................................ ................................ ....................  10 
Preliminary Investigations and Justifications of the Study  ................................ ................................ .....................  10 
Risks and Benefits of the Investigational Device and Clinical Investigation  ................................ ................................  10 
Sensors  ................................ ................................ ................................ ................................ ................................ .... 11 
Nasal Cann ula ................................ ................................ ................................ ................................ .........................  11 
General Electrical Hazards  ................................ ................................ ................................ ................................ ...... 11 
Benefits  ................................ ................................ ................................ ................................ ................................ ... 11 
Design of the Clinical Investigation  ................................ ................................ ................................ .............................  11 
Method  ................................ ................................ ................................ ................................ ................................ ... 11 
Video and/or Photos  ................................ ................................ ................................ ................................ ...............  12 
Equipment  ................................ ................................ ................................ ................................ ...............................  12 
Study Population  ................................ ................................ ................................ ................................ .....................  13 
Inclusion Criteria  ................................ ................................ ................................ ................................ .................  13 
Population Criteria to be Included  ................................ ................................ ................................ ......................  13 
Exclusion Criteria  ................................ ................................ ................................ ................................ ................  13 
Fitzpatrick Scale  ................................ ................................ ................................ ................................ ..................  14 
Duration of Clinical Investigation  ................................ ................................ ................................ ............................  14 
Criteria for Study Termination  ................................ ................................ ................................ ................................  14 
Procedure  ................................ ................................ ................................ ................................ ................................ ... 14 
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_432998]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   7   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Statistical Analysis  ................................ ................................ ................................ ................................ .......................  15 
Endpoint / Comparator  ................................ ................................ ................................ ................................ ...........  [ADDRESS_432999] (IRB)/Indep endent Ethics Committee (IEC)  ................................ ................................ . 17 
Monitoring Arrangements  ................................ ................................ ................................ ................................ ...... 17 
Monitoring Plan  ................................ ................................ ................................ ................................ ......................  18 
Data and Qua lity Management / Confidentiality  ................................ ................................ ................................ .... 18 
Records - Study Documentation / Case Report Forms  ................................ ................................ ...........................  19 
Participant Documents  ................................ ................................ ................................ ................................ ...........  19 
Data Collection Forms / Case Report Forms  ................................ ................................ ................................ ...........  19 
Trial Master File Documents  ................................ ................................ ................................ ................................ ... 20 
Amendments to the Clinical Investigation Plan  ................................ ................................ ................................ ...... 20 
Deviations from the Clinical Investigation Plan  ................................ ................................ ................................ ...... 20 
Device Accountability  ................................ ................................ ................................ ................................ .............  21 
Device Deficiencies  ................................ ................................ ................................ ................................ .................  21 
Packaging and Labeling  ................................ ................................ ................................ ................................ ...........  21 
Storage and Accountability  ................................ ................................ ................................ ................................ ..... 21 
Statement of Compliance  ................................ ................................ ................................ ................................ .......  21 
Reference Document s ................................ ................................ ................................ ................................ .........  21 
Informed Consent Process  ................................ ................................ ................................ ................................ ...... 22 
Safety  ................................ ................................ ................................ ................................ ................................ ...... 22 
Investigators  ................................ ................................ ................................ ................................ .......................  22 
Participant  ................................ ................................ ................................ ................................ ...........................  22 
Adverse Event Definitions  ................................ ................................ ................................ ................................ ... 22 
Management of Adverse Event Reporting  ................................ ................................ ................................ ..............  23 
Reporting of Serious Adverse Events and / or UADE  ................................ ................................ ..............................  23 
Sponsor Records and Reports  ................................ ................................ ................................ ................................ . 23 
Records 21 CFR 812.140 (b) 4,5  ................................ ................................ ................................ ..........................  23 
Reporting 21 CFR 812.150 (b) 1,2,3,5,6,7,8,9,10:  ................................ ................................ ...............................  [ADDRESS_433000]  ................................ ................................ ................................ ..................  24 
Withdrawal of IRB approval  ................................ ................................ ................................ ................................  24 
Withdrawal of Regulatory Authorities approval  ................................ ................................ ................................ . 24 
Progress Reports  ................................ ................................ ................................ ................................ .................  24 
Recall and device  ................................ ................................ ................................ ................................ ................  24 
Final Report  ................................ ................................ ................................ ................................ .........................  24 
Informed consent  ................................ ................................ ................................ ................................ ................  24 
Significant risk device determinations – (does not apply to NSR studies)  ................................ ..........................  24 
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433001]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   8   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Other  ................................ ................................ ................................ ................................ ................................ ... 24 
Investigators Records and Reporting  ................................ ................................ ................................ ......................  25 
Records 21 CFR 812.140 (a)(3)(i)  ................................ ................................ ................................ .........................  25 
Reports 21 CFR 812.150 (a) 1,2,5,7  ................................ ................................ ................................ .....................  25 
Unanticipated adverse device effects  ................................ ................................ ................................ .................  25 
Withdrawal of IRB approval  ................................ ................................ ................................ ................................  25 
Informed consent  ................................ ................................ ................................ ................................ ................  25 
Other  ................................ ................................ ................................ ................................ ................................ ... 25 
Withdrawal, Early Termination or Suspension of the Investigation  ................................ ................................ .......  25 
Publication Policy  ................................ ................................ ................................ ................................ ....................  26 
Attachment A - Protocol Signature [CONTACT_3490]  ................................ ................................ ................................ ....................  27 
Appendix B: Sample Waveform Scoring Form  ................................ ................................ ................................ ............  28 
 
 
 
  
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433002]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   9   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Respi[INVESTIGATOR_348525] - Gabi SmartCare Gabi Band   
PR [ADDRESS_433003] a Respi[INVESTIGATOR_348531], an FDA cleared End Tidal Carbon Dioxide monitor (GE Datex -Ohmeda).  
 
The testing will be conducted in order to obtain a full data set for Verification  on a minimum of [ADDRESS_433004] ed independent of developmental data sets.  The study will be split up into two 
phases:  
• Phase I with a minimum of 8 subjects  
• Phase II with a minimum of 15 subjects  
 
Identification and Description of the Investigational Device  
The Gabi device consists of a sensor head with an attached armband to make the wearable device. The sensor 
head contains a photoplethysmography sensor (PPG) and all other electronics. The PPG sensor is seated on the 
underside of the sensor head to maintain skin contact. All data is sto red on the collection tablet and uploaded to 
the Gabi Cloud for analysis when data collection is stopped.  
 
 
 
Figure 1:  The Gabi SmartCare Gabi Band  – The Device Under Test  
 
The intended purpose of the Device Under Test is continuous , non -invasive monitoring on the neonatal, infant, and 
pediatric  population s. For this evaluation, the device will be run in a continuous data collection mode. The 
accompanying acquisition software  will be provided by [CONTACT_348556] . 
 
The Gabi SmartCare Gabi Band  are investigational and has not been cleared by [CONTACT_1622].  The sensor  and the  arm 
band  are the components expected to come in contact [CONTACT_6635] s. 
 
Instructions for use, storage and handling can be found in the Device Operator’s Manual.  Device model numbers, 
software version, serial numbers, date(s) of use,  and participant  ID numb er(s) will be recorded on the Case Report 
Forms.   
                                  
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433005]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   10   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
All appropriate testing to demonstrate safety for use in human studies prior to Clinimark’s receipt of the device  
was completed . Such documentation will reside in the design history files of the Sponsor. Documentation will be 
provided regarding the safety of the investigational  device .  
 
Data Acquisition System for the I nvestigational Device  
The data from the investigational devices /smartphone  will be collected by a trained member of Clinimark, separate 
from the Clinimark automated data collection system.  
 
Safety Equipment  
Patient  monitor (s) used during the study to observe a participant ’s vital signs including SpO2, pulse  rate, 
respi[INVESTIGATOR_697], end -tidal CO 2 with capnograph : 
• SpO [ADDRESS_433006] PR (K993608) or E-PRESTN (K031781) 
module, and/or other Multi -parameter monitor , GE Healthcare (Datex -Ohmeda) 3900 TruTrak+ , GE 
Healthcare S5 Compact Monitor with M-NESTPR  (K993608)  or E-PRESTN (K031781) module , and/or 
Nellcor N600x Pulse Oximeter  
• EtCO 2 Capnography / Res pi[INVESTIGATOR_13581] - GE Healthcare S5 Compact Monitor with M-COVX (K001814) or E-
CaiO (K051092) modules  
• Portable oxygen tank, mask and ambu bag  
• Blood pressure cuff and stethoscope  
 
Preliminary Investigations and Justifications of the Study  
Gabi SmartCare  is dedicated to developi[INVESTIGATOR_348532] . As part of the product development, Gabi SmartCare  retained the services 
of Clinimark, LLC to conduct a respi [INVESTIGATOR_348533].  
 
Studies previously conducted at Clinimark:  
• Clinimark Study ID# PR 2022 -477 “SpO2 Verification and Optional Calibration Study”  
 
Risks and Benefits of the Investigational De vice and Clinical Investigation  
The devices under test in this study are considered non -significant risk devices. The device and use of the device 
under test does not meet the definition of significant risk device under 21 CFR 812.3(m)  
 
For the purpose of this study:  
• It is not intended as an implant.  
o Sensors are applied to the surface of the area and is removed following data collection typi[INVESTIGATOR_348534] 1 day.  
• It is not purported or represented to be for use in supporting or sustaining human life, nor does it present 
a potential for s erious risk to the health, safety, or welfare of a participant .  
o Monitors  are not used to support or sustain human life.  
• It is not for use of substantial importance in diagnosing, curing, mitigating, or treating disease, or 
otherwise preventing impairment of human health  
o Monitors are Class II devices used to  measure respi[INVESTIGATOR_697] . They are not used to diagnose, 
cure, mit igate, or treat disease. These devices are typi[INVESTIGATOR_348535] a general indication for 
non-invasive measurement of respi[INVESTIGATOR_697] . 
• The device as used in this investigation does not present a serious risk to the health, safety, or welfare of 
a partici pant . 
o See below for discussion of risk associated with the device and use of the device.  
 
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433007]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   11   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
There are no anticipated risks or adverse device effects to be assessed. There are no contraindications for use in 
the proposed study / study population. There may be other risks to the participant  associated with the device or 
procedure that are unforesee able at this time.  
 
Sensor s 
Sensor placement involves positioning sensors on volunteer participant  in the same manner that is used on 
hospi[INVESTIGATOR_9643] . The sensors may be warm to the touch. Under normal operating conditions, no fault 
conditions, the sensors are not expected to overheat. If the sensors are too warm, they will be removed 
immediately.  Adhesive sensors or tape may cause some irritations to t he skin in some participant s. Every effort 
will be made to minimize products with natural rubber or latex. Products containing natural rubber or latex will be 
identified.  The risk in the use of the sensor is believed to be minimal . 
 
Nasal Cannula  
The nasa l cannula are made of soft, flexible plastic so as to minimize the discomfort level as much as is reasonably 
possible. Materials may cause some skin irritations. Insertion and removal of a nasal cannula may cause nasal 
irritation, discomfort, or pain.  
 
General Electrical Hazards  
Electrical hazards are a potential risk with all electrical equipment. The equipment used in this study has been 
designed to meet applicable safety standards. The equipment will be safety and functionally tested prior to 
participant  use. The possibility of any electrical hazard is extremely remote.  
 
Benefits  
The benefits to the study are to the advancement of non -invasive medical monitoring of patients by [CONTACT_164284]. There are no direct benefit s to the participant s involvement  in this 
study other than being a paid volunteer. The only alternative to this study is to NOT participate.  
 
Design of the Clinical Investigation  
Method  
The purpose of this study is to conduct a Respi[INVESTIGATOR_348527], an FDA cleared End Tidal Carbon Dioxide monitor (GE Datex -Ohmeda).  
 
This study is a comparative, single -center, non -randomized study in a minimum of [ADDRESS_433008] is expected to take approximately 1 -2 hours. Typi[INVESTIGATOR_897], up to 4 participant s will be 
run per day.  It is expected that the data collection will take two days for Phas e II and four day s for Phase II . A 
maximum of 60 participant s will be enrolled. An attempt will be made to include 3 darkly pi[INVESTIGATOR_348536] s 
(Fitzpatrick of 5 or 6) or 15% of the participant  pool (whichever is larger).  Participant s will be from 0 -12 years of 
age with the following distribution:  
 
Population  Age Population  Requirement  
Neonates  0-28 Days  No requirement  
Infant  >1 month – 24 months  Minimum 30% of participants  
Pediatrics  >2 years – 12 years  Minimum 30% of participants  
 
The parent or guardian will be provided an IRB approved Informed Consent. As applicable, parent or guardian will 
be told about any new information that might change their decision to participate. Participant s whose parent or 
guardian have completed the inf ormed consent , completed  the Participant Demographics and Screening Record 
Form,  and met inclusion criteria and none of the exclusion criteria will be enrolled in the study. Participants 
ranging in age 7 –12 years will additionally go through an Assent process.  
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433009]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   12   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
 
Each participant  will be connected to a commonly used End Tidal Carbon Dioxide mon itor (GE Datex -Ohmeda) and 
the Gabi SmartCare Gabi Band. The end tidal carbon dioxide (EtCO 2) monitor will determine performance of 
respi[INVESTIGATOR_348529] (GE Healthcare S5 Compact Monitor with M-COVX (K001814) or E-CaiO (K051092) 
modules ). Each particip ant will be instrumented with neonatal or pediatric nasal cannula that allows for 
measurement of the EtCO 2.  SpO 2 sensors may be placed on the feet and/or toes for safety monitoring purposes.  
 
Data will be simultaneously and continuously recorded from the Reference EtCO [ADDRESS_433010] (DUT). Periods of quiet will be encouraged.  Data will be marked for stable quiet periods that are useable for 
analysis. There is no additional follow -up required for the investigation.     
 
One minute epoch s will be generated from the stable data periods for analysis.   For verification , the Reference 
EtCO 2 waveform will be scored by [CONTACT_348554][INVESTIGATOR_348530] (See Appendix B: Sample Waveform 
Scoring Form for an example).  The reviewers counti ng the raw EtCO [ADDRESS_433011] device. The DUT data will be averaged over the corresponding one minute period.  The Accuracy root -
mean -square (A rms) will be the basis for evaluation and acceptance.  
 
To ‘Pass’ this te st the Gabi SmartCare Gabi Band  (Device Under Test ) must demonstrate a respi[INVESTIGATOR_348537] -mean -square (A rms) of ≤3 .0 breaths per minute when compared to the Reference EtCO 2 monitor . 
 
Video and/or Photos  
In this study photographs or video may be taken of the sensor application sites during sensor application for data 
collection purposes and the Study Sponsor’s internal research and development purposes only. This allows the 
sponsor to analyze the data and observe sensor placement. Pi[INVESTIGATOR_348538]. The study equipment will be photographed, however, in some circumstances it may be 
unavoidable to not photograph the participant ’s face.  In order to protect the participant ’s identity, the name [CONTACT_348570].   
 
Equipment  
The MediCollector software will be used to  collect the reference data .  
 
Description of Medi Collector  
• Computer with data collection software , able to stream data as it is recorded with the ability to add 
annotations  
• Direct cable connection with the Datex -Ohmeda S/5 Multi -parameter Monitor  
• Collects a variety of signals including values displayed by [CONTACT_941] S5 as well as the raw waveforms  
o Up to 8 signals can be collected  
 
Medi Collector –Signal Channels Examples  
# Name  [CONTACT_164301]. of 
Collection (Hz)  Units  
1 CO_RR  Respi[INVESTIGATOR_13581]  0.2 breaths/min  
2 CO2 CO 2 Concentration (RR waveform)  25 % 
 
Safety Equipment  
• GE Healthcare Datex -Ohmeda S/5 Multi -parameter Monitor, M-NESTPR  (K993608)  or E-PRESTN 
(K031781) module with Sp O2, GE Healthcare (Datex -Ohmeda) 3900 TruTrak+ (K021955) and/or 
Nellcor N600x Pulse Oximeter  (K123581)  with appropriate neonatal, infant, or pediatric sensors  
• Portable oxygen tank, mask and ambu bag  
 
Supplies for Participant   
• Neonate or pediatric  nasal cannula for EtCO 2 measurement  
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433012]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   13   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
 
Reference  
• GE Healthcare Datex -Ohmeda S/5 Multi -parameter Monitor, M-COVX (K001814) or E-CaiO (K051092) 
module (Reference EtCO 2) 
 
Investigational Device  
• Gabi SmartCare Gabi Band  (DUT)  
• Computer, t able t, or phone for data capture transfer  
  
There are no deviations expected from this investigation plan. Should deviations be needed, discussi ons will be 
conducted w ith Gabi SmartCare , Principal investigator , and reported to the IRB per the reviewing IRB guidelines.  
 
Study Population  
The study population will include a minimum of 2 3 neonates, infants, and pediatrics from 0 -12 years of age. A 
maximum of 60 participant s will be enrolled.  The partic ipant  selection will be an equitable distribution of males 
and females of any race with varying skin tones.  An attempt will be made to include 3 darkly pi[INVESTIGATOR_348528] s (Fitzpatrick 5 or 6) or 15% of the participant  pool (whichever is larger).  
 
The parents of the participant s must understand the study and consent to their child’s participation in the study by 
[CONTACT_246629].  Subjects 7 to 12 years of age will be provided an Assent. The study will be 
explained within his/her ability  to understand.   Participant  enrollment and participation in this clinical study is 
based on meeting the inclusion criteria and none of the exclusion criteria, a satisfactory screening, and the 
participant  and data demographics needed for the study.   
 
Inclusion Criteria  
• Ability of the parent or guardian to understand and provide written informed consent  
• Participant is 0 to 12 years of age  
• Subjects that are between [ADDRESS_433013] provide Assent to participate in the study  
 
Population Criteria to be Included  
• A minimum of 30% of participants will be >1 month to 24 months old  
• A minimum of 30% of participants will be >2 years to 12 year  
 
Exclusion Criteria  
• Participants evaluated by [CONTACT_348557]-reported health conditions that are currently unstable as identified in the Participant Demographics 
and Screening Record Form  
• Participant has injuries, deformities or abnormalities that may prevent proper application of the device 
under test  
• Participants  with severe contact [CONTACT_136184], latex or other materials found in pulse 
oximetry sensors, ECG electrodes, or other medical sensors (self -reported)  
 
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433014]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   14   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Fitzpatrick Scale  
The Fitzpatrick scale will be used to access skin tone. The followin g chart will be used:  
 
Figure 2:  The Fitzpatrick Scale  
 
Duration of Clinical Investigation  
Each participant  test is expected to take approximately 1 – 2 hours. Typi[INVESTIGATOR_897],  four participant s will be run per day. 
It is expected that the data collection will take 5 to 7 days for verification .  There is no additional follow -up 
required for the investigation.  
 
Criteria for Study Termination  
The study will be terminated if any of the following conditions occurs:  
• Study is complete  
• The participant ’s parent or guardian may stop the study for any reason without prejudice  
• Withdrawal by [INVESTIGATOR_60055] -Investigator / Investigator  
• Study Stopped due to Technical Problems  
• Study may be stopped due to Protocol Deviation  
• Study Terminate d by [CONTACT_2728]  
• Study Stopped due to Adverse Event  
 
Any data collected to the point of a decision to terminate the study will be reviewed for inclusion to the analysis 
prior to generation of the final results. Data excluded from the analysis will be documente d with justifications for 
the Verification  of the product. During the development phase, usage and removal of the data is at the sponsors 
discretion.  
 
Procedure  
1. Complete equipment setup and checkout prior to starting study.  
2. Set and / or synchronize the com puter clocks for the sponsor  and Clinimark data collection systems  
3. Explain the procedure to the participant ’s parent or guardian. Have them read the Informed C onsent 
Form  and review the information , answering all questions. Once all questions have been answered, have 
the parent or guardian sign the form. Have the parent or guardian complete the Participant Demographics 
and Screening Record Form and verbally ques tion the parent or guardian about the health history. Each 
parent or guardian will be asked if they want a copy of the consent form prior to release.  
a. Participants ranging in age 7 –[ADDRESS_433015] accepted or declined from the study. Continue if accepted into the study.  
5. Position participant in the parent’s lap, on bed, or in a chair (for pediatric participants).  
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433016]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   15   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
6. Setup and verify communication between the devices and data collection systems.  
7. Record device information for tracking (manufacturer, model #, serial/lot, hardware/software control 
info).  
8. Record participant  information , participant  number , and demographics information . 
9. Apply a SpO 2 sensor to the participant following the IFU for the pulse oximeter.  
a. Sensors may be placed on the feet or hands.  
b. Supplemental tape may be used to secure the sensors on feet that are too large for the sensor 
bandag e length.  
10. Apply the nasal cannula to the participant.  Use neonatal/infant soft tape as necessary to adhere the nasal 
cannula.  
11. Apply  Device Under Test  sensors to the participant  per the IFU . Adjust sensors  and devices  as appropriate , 
ensur ing the Device Under Test is producing valid outputs, and record the placement on test form.   
12. Allow readings to stabilize  for at least  a few minutes . 
13. Begin Respi[INVESTIGATOR_348539] .  
a. Start data collection and elapsed timer display.  
b. Encourage the participa nt to be quiet.  
c. Mark in MediCollector quiet periods with minimal movement, talking, and /or crying. Note 
motion events , location, position, and activity level of the participant  in the CRF.  
d. Data from the Reference (EtCO 2 waveform) and the DUT will be recorded continuously. 
Additional study notes that describe conditions of the test as well as deviations, device issues, 
and any adverse events will be recorded in written documentation.  
e. Record data for up to [ADDRESS_433017] 
Respi[INVESTIGATOR_348540], stable periods . The data will be paired based on syncing 
of the data collection system clocks. During the stable data sets , the DUT data will b e averaged in approximately 60 
second intervals. The Reference EtCO 2 waveform will be scored by [CONTACT_348554][INVESTIGATOR_348530] (See 
Appendix B: Sample Waveform Scoring Form for an example).  The reviewers counting the raw EtCO [ADDRESS_433018] device.  
 
The final pairing to be analyzed is Reference EtCO 2 scored and counted waveform with the average of the 
simultaneous 60 second period for the DUT. The Accuracy root -mean -square (A rms) will be the basis for eval uation 
and acceptance.  
 
Endpoint / Comparator  
The primary objective of this study is to compare the accuracy of the device under test for the measurement of 
respi[INVESTIGATOR_348541], which is an End Tidal Carbon Dioxide Monitor (EtCO 2). For verifi cation , the EtCO [ADDRESS_433019] is accuracy as measured by [CONTACT_348558] -mean -square (A rms) difference between the 
Device Under Test (DUT) and the Reference Respi[INVESTIGATOR_348542] 2 scored waveform (Ref) for all 
stable respi[INVESTIGATOR_348543]: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433020]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   16   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
 
Mean b ias will also be generated:  
 
 
Acceptance Criteria: Passing requires an A rms of ≤3.0cpm . 
 
Sample Size Justification  
This study will utilize a sample size of 20 participant s with 7 to 11 usable data points per participant , providing 
>200 data points over the specified breath per minute range.  
 
Success for this study is defined as A RMS £ 3cpm . The A RMS statistic measures accuracy of a device under test (DUT) 
when compared to a reference device (REF) over a range of values. Accuracy, measured by [CONTACT_941] A RMS statistic, can 
be affected by [CONTACT_348559]. Here we estimate power to obtain an A RMS £ 
3cpm  for this study through simulation using parameters estimated from two preliminary studies  conducted 
previously by [CONTACT_348560] . Respi[INVESTIGATOR_348544] [ADDRESS_433021] respi[INVESTIGATOR_348545] ‘Summary of Respi[INVESTIGATOR_348546]’ dated May 1, 2019. These 
preliminary data contain the features of real data, such as within participant  correlation that is present due to 
repeated measurements on the same study participants. Note this sample size was conducted on studies with 
adult populations  where paced breathing can be used to get a range of repository rates.  Participants in this stud y 
will breathe  at their natural rate.  
 
Repeated measures within participant s is a common practice in the pulse oximetry field but is known to potentially 
lead to within participant  correlation, which is accounted for in these power estimates. Linear mixed  models 
(LMM) were used to estimate parameters for each study in order to take into account repeated measures within 
participant s. DUT was treated as the dependent variable. Participant  was treated as a random effect, and REF was 
treated as a fixed effect.  Parameter estimates from the mixed model were used as parameter estimates for 
simulations. The variance between participant s in the mixed model results were used to model within individual 
correlation. Residual variance was used to model variance within participant s. The estimated effect of REF was 
modeled as slope. The simulation model also incorporated mean bias. The simulation model was as follows:  
𝐷𝑈𝑇!"=𝑚×𝑅𝐸𝐹!"+	𝐵+	𝜎#
$%&'%%( +	𝜎#
'!&)!( 
• 𝑚 = slope;  𝐵 = mean bias; 𝜎# = variance ; 
• 𝑖 = measure; 𝑗 = individual  
Simulations were performed for the studies with a range of [ADDRESS_433022] c onservative power estimates, and are as follows:  
𝑚:0.[ZIP_CODE]  
𝐵: -0.[ZIP_CODE]  
𝜎#
$%&'%%( : 0.4724  
𝜎#
'!&)!(: 7.[ADDRESS_433023] >80% to obtain 
ARMS £ 3cpm : (Participant s x measurements) 27x9, 16x18, 11x27, 10x36. A study design with 30 participant s and 18 
measurements per participant  has >80% power to obtain A RMS £ 3cpm  given the expectation that the device 
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433024]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   17   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
performs the same as Study 1. Statistical modeling and simulations w ere performed using R (R 3.5.3 GUI El Capi[INVESTIGATOR_348547], the R Foundation for Statistical Computing, 2016).  
 
 
Figure 3 – Plot of estimated power based on the number of participant s and measurements per respi[INVESTIGATOR_348548] (IRB)/Independent Ethics Committee (IEC)  
Prior to the start of participant  enrollment, the primary investigator will be responsible for obtaining approval from 
the authorized IRB/IEC for the institution at which the proposed clinical investigation is to be  conducted. Written 
approval from the IRB/IEC should specifically refer to the investigator, the protocol title and date, and participant  
informed consent date.  Written IRB/IEC approval and any conditions of approval imposed by [CONTACT_1201]/IEC will be 
obtained  by [CONTACT_34351].  
 
Protocol amendments must also undergo IRB/IEC review and approval at each clinical site. The written approval 
from the IRB/IEC for the amendment should specifically refer to the investigator, the protocol version number and 
title, and any amendment numbers that are applicable.  
 
Monitoring Arrangements  
Clinimark personnel  (Louisville, C O, [LOCATION_003] ) will provide all monitoring. The Monitor shall be responsible for 
maintaining a record of the findings, conclusions, and actions taken for the results of monitoring the study 
ensuring that:  
 
The monitoring requirements for an NSR device study is identified in 21 CFR 812.2(b) Abbreviated requirements. 
For monitoring an NSR device investigation, the requirement is to comply with [ADDRESS_433025] to 
monitoring investigations: (a) Securing Compliance, (b) Unanticipated adverse device effects, (c) Resumption of 
terminated studies  
• Compliance to the signed agreement between the Investigator and sponsor  
• The study follows the protoc ol and any amendments that apply  
• Compliance to any conditions of the approval imposed by [CONTACT_348561]:  
• The conditions for the study continue to be acceptable  
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433026]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   18   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
• Accurate, complete, and current records are maintained and req uired reports are written  
• Any adverse effects are documented and reported to the Sponsor and IRB as appropriate  
• Monitor activities may include for example:  performing source data verification and requesting 
corrections to feedback forms where potential in consistencies or missing values are identified.  
• Findings of non -compliance or required modifications are reviewed with the investigator and the Sponsor, 
and is presented in a written report to both  
• Providing a Monitoring Report at the end of the Clinical Investigation  
 
Monitoring Plan  
1) Informed Consent  
• Verify that the consent form was signed prior to any study procedures being conducted  
• Verify that the staff conducting the consent is listed for approval on the Delegation of Authority Log  
• Ensure that the co nsent process is documented.  
2) Participant  Eligibility  
• Verify that the participant  meets the inclusion criteria and none of the exclusion criteria.  
3) Baseline Data  
• Verify demographic information with the Participant Demographics and Screening Record Form  
• Check that informed consent time and date is prior to start of the procedure  
4) Verify all CRFs are completed  
5) Adverse Events  
• Verify that Adverse Events and Serious Adverse Events / UADEs are being reported accordingly to the IRB 
and Sponsor in the required ti meframe.  
6) Protocol Deviations  
• Verity that Protocol Deviations are being reported accordingly to the IRB and Sponsor in the required 
timeframe  
7) Electronic Data Review  
• Verify that the filename [CONTACT_164303]  
8) Ensure the Trial Master Fil e is complete.  
 
Data and Quality Management / Confidentiality  
A checklist will be maintained identifying the contents of the Trial Master File / Project folder PFC# 2022 -495. 
 
The participant ’s name [CONTACT_348571] s will be recorded on the Informed Consent, Participant 
Demographics and Screening Record Form , Assent Form (if applies), and a participant  scheduling list. The data 
collection form will only use a participant  number for the day of the test along with participant  demographics. A 
name [CONTACT_164305].  
 
Records identifying the participant ’s name [CONTACT_7637] a secured location with either a locked file or locked 
door.  Access to t hese files will be on a limited basis. Potential reviewers of this information include: Clinimark 
representatives collecting the information and conducting the study, Medical Director for Clinimark,  Regulatory 
Authorities , Department of Health and Human Se rvices (DHHS) agencies, Governmental agencies in other 
countries, Salus Independent  Review Board and representatives of the Sponsor. This group may use the 
information to conduct independent audits and reviews to verify compliance of the regulatory require ments for 
these studies but not copy the information.  
 
Data files stored electronically will be associated with a participant  based off of participant  #, date and by [CONTACT_348562]. The original device electronic data files  will be preserved in its original form. 
Data analysis will be performed as a separate electronic file.   
 
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433027]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   19   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Data files, data collection records with participant  demographics and participant  number may be additionally 
copi[INVESTIGATOR_530], (after de -identification, if app licable) reviewed and supplied to the commercial sponsor for the study or 
Contractors associated with Clinimark for data analysis purposes.  
 
All study records will be stored for at least [ADDRESS_433028] cancellation. The 
investigator will notify sponsor prior to destruction of study records.  Other storage arrangements may be 
executed per contractual agreement  between the sponsor and the investigator.  
 
Records - Study Documentation / Case Report Forms  
Respi[INVESTIGATOR_348525] - Gabi SmartCare Gabi Band   
Clinimark Study ID# PR 2022 -495 
  
Participant  Documents  
Provided as separate documents to this protocol : 
• Parental Permission Informed Consent form (IRB approved)  
• IRB Approved Assent Form - Assent Document For Minors 7 to 12 years of age  
• [ADDRESS_433029] Form (F2000 -001-009 modified for 2022 -495)  
 
Study Cond uct Documents : 
• CRF2022 -495– Case Report  Forms  
• Electronic Files – electronic data collected from the reference and DUT  system s 
 
Data Collection Forms / Case Report Forms  
To ensure the quality and integrity of the data, it is the responsibility of the Investigator(s) or designee to complete 
the Case Report Forms (CRFs) for each participant  who is enrolled to participate in this study.  In some cases,  the 
data collection form s will also be the source document for some information that is not directly collected in the 
Health Assessment Form. The following information will be recorded on the site’s data collection forms ( CRF): 
• Study date, Participant  ID#, Participant  Initials, a nd Relevant Participant  Demographics, Associated 
Electronic Filename(s)  
o Participant  demographics: gender, age, height, weight, race, ethnicity, skin tone  
• Evidence that informed consent was signed and dated prior to the participant ’s involvement  in the study  
• Baseline vital signs pertinent to the inclusion and exclusion criteria (SpO 2, PR, Blood pressure, etc.)  
• Information for Participant  Inclusion or Exclusion to the study  
• Equipment calibration and communication check out  
• Device usage / sensor placement on the participant  
• Annotations on data point markers, stability, and other observations used in the data analysis  
• Protocol Deviation rep orting  (only if needed)  
• Adverse Events reporting  (only if needed)  
• Device Deficiency reporting (only if needed)  
• Study termination  
 
A black or blue pen will be used to record data on the data collection forms. Recorded information should be 
legible and comp lete. Erroneous entries should be crossed out, corrected with the change, initialed and dated by 
[CONTACT_114654]. The Investigator(s) or designee will sign and date at indicated places on each 
page of the data collection form. The Prot ocol Deviations Reporting can be signed and dated by [CONTACT_348563], otherwise the Sub -Investigator or Investigator should review, sign and date. The Adverse 
Events Reporting should be signed and dated by [CONTACT_164289] a Su b-Investigator or Investigator. The Principal 
Investigator [INVESTIGATOR_348549], sign and date all serious adverse events.  The Investigator or designee will provide a 
final signature [CONTACT_164306] a thorough inspection of all participant  data has been perfor med and will thereby 
[INVESTIGATOR_47933]: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433030]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   20   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
certify the contents of the forms. The Investigator’s Certification Statement will disclose the overall 
documentation, study oversight and certification of the study.   
  
Trial Master File Documents  
• Clinimark Control # B3000 -000-003 - Adverse Events and Protocol Deviation Reporting System  
• Clinimark Control # F2000 -001-015 - Delegation of Authority  
• Clinimark Control # F2000 -001-016 - Device Accountability Form  
• Clinimark Control # F2000 -001-[ADDRESS_433031] Disclosu re 
• Clinimark Control # F2000 -001-022 - Investigator’s Certification Statement  
• Clinimark Control # F2000 -001-027 - Site Personnel Training Log  
• Clinimark Control # F2000 -001-[ADDRESS_433032] Enrollment Log  
• Clinimark Control # F2000 -001-029 - Device Deficiency Form  
• Clinimark Control # F2000 -001-033 - Site Visit/ Monitoring Log  
• Clinimark Control # F2000 -001-034 - Data Clarification Form  
• Clinimark Control # F2000 -001-[ADDRESS_433033]  
• Clinimark Control # F2000 -001-037 - Protocol Deviation Log  
• Clinimark Control # F2000 -001-038 - Adverse Events Log  
• Clinimark Control # F2000 -001-042 - Adverse Event CRF  
• Clinimark Control # F2000 -001-043 - Protocol Deviation Form  
• Clinimark Control # F2000 -001-[ADDRESS_433034] Screening Log  
• Clinimark Contr ol # F2000 -001-052 - Device Deficiency Log  
• Communications  
• Additional documents include: Investigator brochure if provided, PI [CONTACT_30215], key staff CV or resumes, 
Correspondence with IRB, IRB voting list, signed contract (optional), insurance certificates, shippin g 
records, SIV / Monitoring documentation, names and contacts for key staff & sponsor, relevant sponsor 
correspondence, customer provided documentation, Final report.  
Current revision of documents applies.  
 
Amendments to the Clinical Investigation Plan  
The sponsor  or Clinimark  may need to make protocol changes during the study. Such amendments will be 
documented, reviewed and changes will be submitted to the sponsor  for first approval, then to the IRB for 
approval. The sponsor  and site will make a decision regarding the continu ation of participant  enrollment during 
this period. The site may proceed with the amendment upon receipt of IRB approval.  
 
Deviations from the Clinical Investigation Plan  
Investigators are not allowed to deviate from the Clinical Investigation Plan  (CIP) e xcept under emergency 
circumstances. Deviations from the CIP to protect the rights, safety and well -being of human participant s may 
proceed without prior approval of the sponsor and the IRB. Such deviations shall be documented and reported to 
the sponsor a nd the IRB as soon as possible but within [ADDRESS_433035] of the study will be documented in the case 
report forms, regulatory binder Protocol Deviation Log as app ropriate.  
  
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433036]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   21   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Device Accountability  
A Device Accountability Log will be maintained for the sponsor’s equipment documenting date of receipt, 
description of device (including model#, lot#, serial number or unique code, and quantity)  and date of return for 
used and unused product.  Device usage will be recorded in the Case Report Form for each individual participant . 
 
Device Deficiencies  
A Device Deficiency Log will be maintained during the study.  Upon a device deficiency, a Device Def iciencies Form 
will be filled out and is also marked on the participant ’s CRF.  Any device deficiency regarding the operation of the 
device or software or any malfunctions are to be reported to the sponsor. The sponsor will provide a follow up 
investigatio n to the deficiency.  
 
Packaging and Labeling  
Research conducted for this study will utilize investigational devices and devices cleared through the 510k 
regulatory process. The Sponsor is responsible for packaging and labelling of the device for delivery t o the study 
site. Investigational devices or its immediate package shall bear a label with the following information: name [CONTACT_348572], packager, or distributor, the quantity of contents, if appropriate, and the following 
statement:  
“CAU TION - Investigational device. Limited by [CONTACT_4496] (or [LOCATION_002]) law to investigational use.”  
 
The label or other labeling shall describe all relevant contraindications, hazards, adverse effects, interfering 
substances or devices, warnings, and precaut ions.  
 
It is the investigator’s responsibility to ensure the appropriate labelling is visible and remains intact throughout the 
life of the study.  
 
The Instructions for Use (IFUs) are provided as separate documents from this protocol.  
 
Storage and Accounta bility  
The site will store the investigational product. The storage area should be locked/secure with access limited only to 
approved study staff.  
 
The site will record/track use of the investigational device by [CONTACT_20908]. Documentation should veri fy that 
the device use was in accordance with the approved protocol. Equipment Document in the Case Report Form shall 
provide documentation of the devices used on the study participant(s).  
 
Statement of Compliance  
The study will be conducted in accordance with the Declaration of Helsinki, 21 CFR 50, and 21 CFR 812  for non -
significant risk device study investigations . The study will not commence until the approval has been received from 
the IRB.  
 
Reference Documents  
IRB Approved Informed Consent for Study Title:  Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band  Study  ID# PR  2022 -495 
• ISO [ADDRESS_433037] edition 2011 -04-01, applicable sections, Clause 50 and Annex EE.3 Medical electrical 
equipment — Part 2 -61: Particular requirements for basic safety and essential performance of pulse 
oximeter equipment  
• FDA Guidance Document for Pulse Oximeters, March 4, 2013  
• World M edical Association Declaration o f Helsinki, Ethical Principles for Medical Research Involving 
Human Subjects  
• ISO [ZIP_CODE]:2011  Clinical investigation of medical devices for human subjects — Good clinical practice  
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433038]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   22   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
o FDA recognition of ISO [ADDRESS_433039] edition 2020 -07.  FDA will accept decl arations of conformity to ISO [ZIP_CODE] 
Second edition 2011 -02-01 until 18 December 2022.  
• Clinimark Adverse Events R eporting Document B3000 -000-003 (current revision)  
 
Informed Consent Process  
• The Principal Investigator [INVESTIGATOR_022] / her designee conducts the infor med consent process  
• Verify that the participant ’s parents or guardian  acknowledges ability to read English  
• Instruct the participant ’s parent or guardian  to ask questions at any time during this process, especially 
about things they do not understand.  
• Allow  participant ’s parent or guardian ample time to read the entire form and ask questions.  
• Give a thorough description of the study and the participant ’s involvement – especially explain that the  
parent or guardian  may withdraw the participant from  study at a ny time.  
• After the participant ’s parent or guardian  has read the form ask if they understand everything  
• Ask if they would like  their child to take part in the study and if so explain that they may sign and date the 
form.  
• Once the participant ’s parent or guardian  has signed and dated the informed consent, the principal 
investigator [INVESTIGATOR_348550].  
• Give a copy of the informed consent to the participant ’s parent or guardian  
• No procedure may be performed before the informed  consent is signed by [CONTACT_2299] ’s parent or 
guardian  
 
If an investigator uses a device without obtaining informed consent, the investigator shall report such use to the 
sponsor and the reviewing IRB within [ADDRESS_433040] their child’s  health during the test. The  parents  
or legal guardians  of the  subject may withdraw  the participant from the study at any time. The participa nt may 
be withdrawn per the Procedure section below.   
 
A clinician will be present to monitor the participant  at all times. Safety monitoring includes, SpO 2, pulse rate, 
respi[INVESTIGATOR_697] , direct observation and communication with the participant and parents or legal guardians . 
 
Adverse Event Definitions  
The definitions for adverse event, adverse device effect, serious adverse event, serious adverse device effect, 
unanticipated adverse dev ice effect, and their classifications are provided below (ISO [ZIP_CODE], 21 CFR 812.3).  
• Adverse Device Effect (ADE):  Adverse event related to the use of an investigational medical device 
resulting from insufficiencies or inadequacies in the instructions for us e, the deployment, installation, 
the operation, or any malfunction of the investigational medical device or from error use.  
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433041]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   23   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
• Adverse Event (AE): Any untoward medical occurrence, unintended disease or injury or any untoward 
clinical signs (including an abnor mal laboratory finding) in participant s, users or other persons 
whether or not related to the investigational medical device or investigational procedure  
• Anticipated Serious Adverse Device Effects (ASADE):  ASADE is an effect which by [CONTACT_5942], 
incidence,  severity or outcome has been identified in the risk analysis report.  
• Mild:  a mild adverse event is one in which the participant  is aware of the event, but it is easily 
tolerated without intervention.  
• Moderate:  a moderate adverse event is one that causes s ufficient discomfort to interfere with usual 
activities.  
• Serious Adverse Device Effect (SADE): adverse device effect that has resulted in any of the 
consequences characteristic of a serious adverse event  
• Serious Adverse Event (SAE):  a serious adverse event is an adverse event that results in death, 
inpatient hospi[INVESTIGATOR_059], severe or permanent disability, a life threatening illness or injury, fetal 
distress, fetal death, a congenital abnormality, a birth defect, or medical or surgic al intervention to 
prevent permanent impairment to body or structure.  
• Severe:  a severe adverse event is one that results in the inability to perform usual activities.  
• Unanticipated Adverse Device Effect (UADE):  serious adverse device effect which by [CONTACT_110039] n ature, 
incidence, severity or outcome has not been identified in the current version of the risk analysis 
report.  
 
Management of Adverse Event Reporting  
Should the participant  experience an adverse or non -typi[INVESTIGATOR_164272], assessment of the situation is first initiated and 
a determination will be made of appropriate actions. The Medical Director and Principal  Investigator [INVESTIGATOR_348551]. Adverse Events are report ed through standard Clinimark Procedures, IRB requirements 
and per  Gabi SmartCare  SOPs.   
 
Records of Adverse events will be recorded in the Case Report Form  
The following information will be obtained:  
• Type of effect (ADE, AE. ASADE, SADE, SAE, UADE)  
• Date of onset and resolution  
• Intensity (mild, moderate, severe)  
• Serious (yes/no)  
• Relationship to device (unknown, not related, possibly related, probably related, definitely related)  
• Anticipated (yes/no)  
• Treatment given and / or action taken (procedure stopped,  withdrawn from study, no action)  
 
Reporting of Serious Adverse Events and / or UADE  
All SAE’s, SADE, ASADE and UADE will be reported in writing to the Principal Investig ator, Medical Director Sponsor 
and IRB as soon as possible and no later than [ADDRESS_433042] learns of the event.  
 
If the event resulted in death of a participant , the event shall be reported to the Principal Investigator,  Clinimark  
Medical Director, Sponsor and IRB within 24hrs of knowledge of the event.  
 
Spon sor Records and Reports  
Records 21 CFR 812.140 (b) 4,5  
The following records shall be consolidated in one location and available for  inspection and copying by 
[CONTACT_18332] :  
• The name [CONTACT_29774];  
• A brief explanation of why the device is not a significant risk device:  
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433043]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   24   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
• The name [CONTACT_29775]:  
• The name [CONTACT_29776]:  
• A statement of the extent to which the good manufacturing practice regulation in part 820 will be 
followed in manufacturing the device; and  
• Any other information required by [CONTACT_348564]   
• Records concerning adverse device effects (whether anticipated or unanticipated) and complaints   
 
Reporting 21 CFR 812.150 (b) 1,2,3,5,6,7,8,9,10:  
The sponsor shall prepare and submit the following complete , accurate, and timely reports.  
 
Unanticipated Adverse Device Effect  
A sponsor shall immediately conduct an evaluation of an unanticipated adverse device effect. The results of 
such evaluation shall be reported to the Regulatory Authorities , IRB and participating investigators as soon as 
possible and not later than  [ADDRESS_433044] yearly.  
 
Recall and device  
The sponsor shall notify Regulatory Authorities and all reviewing IRB's of any request that an investigator 
return, repair, or otherwise dispose of any units of a device. Such notice shall occur within [ADDRESS_433045] was made.  
 
Final Report  
The sponsor shall submit a final report to the IRB with in 6 months after termination or completion of the 
investigation.  
 
Informed consent  
The sponsor shall submit to Regulatory Authorities  a copy of any report by [CONTACT_348565] 
(a)(5) of this section of use of a device without obtaining informed consent, within 5 working days of receipt of 
notice of such use.  
 
Significant risk device determinations – (does not apply to NSR  studies)  
If an IRB determines that a device is a significant risk device, and the sponsor had proposed that the IRB 
consider the device not to be a significant risk device, the sponsor shall submit to Regulatory Authorities a 
report of the IRB's determina tion within [ADDRESS_433046] learns of the IRB's 
determination.  
 
Other  
A sponsor shall, upon request by a reviewing IRB or Regulatory Authorities , provide accurate, complete, and 
current information about any aspect of the investigat ion.  
 
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433047]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   25   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Investigators Records and Reporting  
Records 21 CFR 812.140 (a)(3)(i)  
The investigator maintains records of each participant ’s case history and exposure to the device and 
supporting data including signed and dated consent forms, health assessment fo rm, and progress notes during 
the study. Records should show evidence that informed consent was signed and dated prior to the 
participant’s  involvement  in the study.  
 
Reports 21 CFR 812.150 (a) 1,2,5,7  
The investigator shall prepare and submit the followi ng complete, accurate, and timely reports:  
 
 
Unanticipated adverse device effects  
The investigator shall submit to the sponsor and to the reviewing IRB a report of any unanticipated adverse 
device effect occurring during an investigation as soon as possib le, but in no event later than [ADDRESS_433048].  
 
Withdrawal of IRB approval  
The investigator shall report to the sponsor, within 5 working days, a withdrawal of approval by [CONTACT_348566]'s part of an investigation.  
 
Informed consent  
If an investigator uses a device without obtaining informed consent, the investigator shall report such use to 
the sponsor and the reviewing IRB within [ADDRESS_433049] of the investigation.  
 
Withdrawal, Early Termination or Suspension of the Investigation  
Participation in the study is voluntary. The parents or legal guardians may choose to withdraw  the participant  from 
the study at any point. If a participant  officially withdraws from the study, the laboratory staff will document the 
reason for withdrawal in the case report . 
  
Participation in the study may also be stopped at any time by [CONTACT_348567] s ub-investigators 
or sponsor.  
• The participant ’s failure to cooperate fully (as determined by [CONTACT_348568]) 
with the required conduct of this study.  
• The participant ’s develop ment of an illness as determined by [CONTACT_348568].  
• A determination by a Clinimark representative (in his or her sole discretion), for whatever cause, that the 
study should be discontinued.  
• A determination by [CONTACT_456] (in  his or her sole discretion), for whatever cause, that the study should 
be discontinued  
 
The collection of data for study participant s will cease in the following cases:  
• Participant  completes all study requirements  
• Participant ’s parent or guardian  withdra w consent  
• Investigator’s decision that it is in participant ’s best interest to be discontinued from the study  
• Participant  death  
• Adverse event other than death requiring withdrawal of the participant  from the study  
• Determination that the participant  was in eligible for the study.  
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433050]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   26   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
 
There will not be any follow -up procedures for withdrawn or discontinued participant s required, unless a follow -up 
is required a t the Investigator’s discretion . 
 
Consideration for early termination or suspension of the investigatio n is tied to unanticipated equipment failure or 
a decision by [CONTACT_348569]. Both  Gabi SmartCare  and Clinimark reserve the right to discontinue the study 
at any time for administrative or other reasons. Written notice of study termination will be  submitted to the 
investigator in advance of such termination. Termination of a specific site can occur because of, but not limited to, 
inadequate data collection, low participant  enrollment, or non -compliance with the protocol or other research 
requirements.  
 
Early termination results when the study is  closed prior to the end of the study. A study suspension is  a temporary 
postponement of the study activities related to enrollment. Both are possible for the study.  If the study is 
terminated or suspended, no additional enrollment will be allowed unless otherwise informed by [CONTACT_456]. The 
current participant s will be followed according to the protocol.  
 
If the study is t erminated prematurely or suspended by [CONTACT_456]/investigator, the sponsor /investigator will 
promptly inform the regulatory authorities (if required) of the termination and the reason(s). IRB/IECs will also be 
promptly informed and provided with the reas on(s) for termination or suspension by [CONTACT_456]/ investigator. 
The investigator will promptly inform the participant s and assure appropriate follow -up for the participant . 
 
If the investigator (or IRB/IEC) terminates or suspends the investigation the in vestigator will promptly inform the 
institution (if required) and the IRB/IEC, and provide a detailed written explanation of the termination or 
suspension. The investigator will promptly inform the participant s and assure appropriate therapy and follow -up 
for the participant s. The sponsor will inform the regulatory authorities (if required).  
 
Withdrawal of IRB approval shall be reported to the sponsor by [CONTACT_19452] 2 working days.  
 
In case of early termination of the study, all study participan ts should be followed until the resolution of any 
pending adverse event(s).  
 
Publication Policy  
The re sults of this investigation may  not be submitted for publication.  
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433051]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   27   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Attachment A - Protocol Signature [CONTACT_348573]. PR [ADDRESS_433052] read this protocol, I understand it, and I will work according to 
this protocol and to the ethical principles stated in accordance with the Declaration of Helsinki, 21 CFR 50, and 21 
CFR 812: or the applicable laws and regulations of the country of the study site for which I am responsible, 
whichever provides the greater protection of the individual.  
• Ensuring informed consent of each participant  is obtained prior to the start of any study procedure  
• Ensuring the investigation is conducted according to the Clinical Investigation Plan,  
• Personally conducting or supervising the investigation,  
• Protecting the rights, safety, and welfare of participants,  
• Preparing and maintaining adequate, current, and complete case hist ories or records,  
• Retaining records for two years following the date the marketing application is approved or withdrawn,  
• Furnishing the required reports to the sponsor, including reports of adverse events and study completion,  
• Providing timely reports to t he IRB, including reports of changes in the research activity needed to avoid 
immediate hazards to participants, unanticipated problems involving risks to participants or  others, 
including adverse events to the extent required by [CONTACT_1201],  
• Ensuring that changes are not implemented without prospective IRB approval, unless required to 
eliminate immediate hazard to participants,  
• Complying with all FDA  or Regulatory Authorities  test article requirements,  
• Adequately maintaining control of test articles, includ ing appropriate tracking documentation for test 
articles to the extent that such control and documentation are not centrally administered,  
• Supervising the use and disposition of the test article,  
• Disclosing relevant financial information, and  
• Ensuring that  all associates, colleagues, and employees assisting in the conduct of the investigation(s) are 
informed about their obligations in meeting the above commitments.  
• An investigator shall, upon request by a reviewing IRB , FDA,  or other  Regulatory Authorities  provide 
accurate, complete, and current information about any aspect of the investigation.  
 
  21 Sep 2022  
Signature [CONTACT_164310], MD    
Investigator Name (print or type)    
Principal Investigator    
[INVESTIGATOR_348552], CO [LOCATION_003]    
Location of Facility (City, State, Country)    
 
 
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A
 
 
 
Clinimark  
[ADDRESS_433053]  
Louisville, Colorado [ZIP_CODE], [LOCATION_003]  TITLE: Respi[INVESTIGATOR_348525] – Gabi SmartCare Gabi 
Band       Study ID# PR 2022 -495 
Principal Investigator: [INVESTIGATOR_136170], MD     Site ID # 001  DOCUMENT NUMBER  
PR# 2022 -495 
SHEET   28   of   28 REV 
1 
Confidential & Proprietary to Clinimark, LLC.  
Appendix B: Sample Waveform Scoring Form  
Below is an example of the waveform scoring form.  The reviewers counting the raw EtCO [ADDRESS_433054] device.  
 
 
 
 
Respi[INVESTIGATOR_13581] ________________________________  
 
 
Scorer Name ________________________________  Date ________________________________  
 
 
 
Checked by ______________________________________________________  
 
 
Date ____________________________________________________________  
 
DocuSign Envelope ID: EAB9157F-101B-45AE-A86F-DEAE7689715A